Human CD19 Targeted T Cells Injection(CD19 CAR-T) Therapy for Relapsed and Refractory CD19-positive Lymphoma.

Clinical trial NCT03720457 · UNKNOWN

Trial details

NCT number: NCT03720457
Sponsor: Hrain Biotechnology Co., Ltd.
Status: UNKNOWN
Phase: Phase 1
Study type: INTERVENTIONAL

CD19-positive Diffuse Large B-cell Lymphoma Follicular Lymphoma

Start date: 2018-11-13
Primary completion: 2021-10-01
Enrollment: 18

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.